Endocrine and inflammatory profiles in type 2 diabetic patients with and without major depressive disorder by Adriana Alvarez et al.
Alvarez et al. BMC Research Notes 2013, 6:61
http://www.biomedcentral.com/1756-0500/6/61RESEARCH ARTICLE Open AccessEndocrine and inflammatory profiles in type 2
diabetic patients with and without major
depressive disorder
Adriana Alvarez1,5*, Jose Faccioli1, Mónica Guinzbourg1, María M Castex1, Claudia Bayón1, Walter Masson2,
Ignacio Bluro2, Andrea Kozak1, Patricia Sorroche1, Lina Capurro1, Luis Grosembacher1, Adrián Proietti1,
Carlos Finkelsztein1, Lucas Costa3, Patricia Fainstein Day1, Arturo Cagide2, León E Litwak1 and Sherita H Golden4Abstract
Background: There is a high prevalence of depression in individuals with type 2 diabetes mellitus. Depressive
disorders are associated with increased medical morbidity and mortality in individuals with diabetes. It has been
demonstrated that there is a higher prevalence of diabetic complications among individuals with diabetes and
depression compared to those without depression. Several biological alterations have been reported in individuals
with depressive disorders, particularly abnormal levels of endocrine-inflammatory markers.
This study aims to determine the prevalence of major depressive disorder (MDD) in type 2 diabetes patients, the
prevalence of cardiovascular events in individuals with and without MDD and to compare the endocrine-
inflammatory profile between groups.
Methods: The study was approved by the “Comité de Etica de Protocolos de Investigación del Departamento de
Docencia e Investigación del Hospital Italiano de Buenos Aires” with the number “1262” and included only patients
who provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki
and the Habeas Data law on protection of personal data (Law Nª 25326, Argentina).
Type 2 diabetes patients (n = 61) were included and they were classified as having MDD or not according to
DSM-IV. Macrovascular disease was obtained from the medical history. Additionally, the intima-media thickness
of the common carotid, carotid bifurcations and internal carotid arteries was measured non-invasively by
two-dimensional ultrasound imaging. Fasting glucose, fasting lipid profile, inflammatory (CRP, TNF-α) and endocrine
(urine free cortisol and saliva cortisol) markers. Student t tests were used to compare means for normally distributed
variables and Mann-Whitney test for variables without normal distribution. Relative frequencies were calculated and
a chi-square analysis was conducted. Data were expressed as mean ± standard deviation (SD) or median and
interquartile range. Multivariable logistic regression was used to determine the relative odds of clinical
cardiovascular disease in individuals with compared to those without depression. Differences were considered
significant using a two-sided p < 0.05.
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Results: 21 patients (34%) had MDD and 40 patients (66%) didn’t have MDD. Diabetic patients with MDD had
significantly higher CRP levels (4.1(1.9-7.6) vs 1.5(0.5-4.4) mg/l; p = 0.02) and 24-hour urine free cortisol (71.4 ± 21.3 vs
59.8 ± 29.3 ug/24 h; p = 0.03). The other metabolic and inflammatory parameters were not statistically different
between groups. There was a significantly higher prevalence of cardiovascular events in individuals with MDD: 38%
for the depressive group vs 15% for non-depressive group, p = 0.04). Patients with MDD had a 3.5-fold greater odd
of having cardiovascular disease.
Conclusions: Diabetic patients with depression are more likely to have cardiovascular events, and different factors
can determine this high association.
Keywords: Depression, Type 2 diabetes mellitus, Cardiovascular diseaseBackground
Type 2 diabetes is a chronic illness with established cross-
sectional and longitudinal relationships with depression.
There is a high prevalence of depression in individuals with
type 2 diabetes mellitus. A meta-analysis and two system-
atic reviews [1-3] reported that individuals with diabetes
had a 2.9-fold significantly increased odds of having depres-
sion compared to non-diabetic individuals. Depressive
disorders are associated with increased medical morbidity
and mortality in individuals with diabetes [4]. It was
demonstrated that there is a higher prevalence of diabetes
complications, including retinopathy, nephropathy, neu-
ropathy, macrovascular complications and sexual dysfunc-
tion, among individuals with diabetes and depression
compared to those without depression [5].
Depression has been associated with poor adherence to
diet and exercise regimens and poor glycemic control,
including hyperglycemia and high hemoglobin A1c
(HbA1c) levels [6-8]. Several studies, recently summarized
in a meta-analysis by Mezuk et al [9], have shown that
depression is associated with an approximately 60%
increased risk of type 2 diabetes. Thus, depression is a
modifiable risk factor whose treatment could prevent
the development of type 2 diabetes and improve
glycemic control and health outcomes in patients with
depression and pre-existing diabetes.
Several biological alterations have been reported in
individuals with depressive disorders that might increase
the risk for type 2 diabetes, including activity of the
hypothalamic-pituitary-adrenal (HPA) axis leading to
hypercortisolism, sympathetic nervous system (SNS)
activation, increases in C-reactive protein (CRP) and
inflammatory cytokines as tumor necrosis factor
(TNF)-alpha and interleukin (IL)-6, and alterations in
norepinephrine and serotonin metabolism [4-8].
The aims of this study were (1) to determine the
prevalence of major depression in a sample of indivi-
duals with type 2 diabetes using a diagnostic psychiatric
interview, (2) to determine the prevalence of cardiovas-
cular risk factors and clinical cardiovascular events inindividuals with and without depression and, (3) to




Sixty one patients (30 men and 31 women), aged 18 to 65
years, with physician-diagnosed type 2 diabetes mellitus
were included in this observational study. Patients were
recruited from the Diabetes Division, Endocrinology and
Nuclear Medicine Service of Buenos Aires Italian
Hospital, Argentina from 12/05/2008 to 10/12/2009. To
be included in the study, patients had to have been
followed up in the hospital for at least one year and been
able to understand and cooperate with study procedures.
Patients were excluded if they were being treated with cor-
ticosteroids or rimonabant (because they could produce
mood disorders) or had any clinically organic disorder that
could interfere with the results. The study was approved
by CEPI (Comité de Etica para Protocolos de Investiga-
ción del Hospital Italiano de Buenos AIres) a local ethics
committee and included only patients who provided
written informed consent. The study was conducted in
accordance with the Declaration of Helsinki and the
Habeas Data law on protection of personal data (Law Nº
25326, Argentina). Each participant was assigned a number
by which he/she was identified to keep his or her privacy.
Psychiatric evaluation
After the evaluation by a psychiatrist and a psychologist
from the Mental Health Division of the hospital the
patients were classified as having MDD or not according to
Diagnostic and Statistical Manual of Mental Disorder cri-
teria (DSM-IV) [10]. The evaluation included an interview
with the 17-items Hamilton Rating Scale for Depression
(HAM-D17) [11], Mini International Neuropsychiatric
Interview (M.I.N.I.) [12] and Beck Depression Inventory
(BDI) [13] for depression severity assessment. HAM-D17
scale consists of 17 items, which are rated on a scale from 0
to 2 points or 0 to 4 points depending on severity levels.
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sion cut point of 18. The M.I.N.I. is a structured diagnostic
interview that explores the psychiatric disorders. The BDI
is a multiple-choice self-report questionnaire inventory
used for evaluation of subjective consciousness of depres-
sive symptoms and also allows analysis of cognitive versus
somatic symptoms of depression. The cut-off value for
depression was 24 for the Hamilton scale. Additionally,
family history of depression was documented.Clinical evaluation
A complete medical history was taken and anthropometric
data were collected. Weight and height were measured
to calculate body mass index (BMI = weight/ height2
[Kg/ m2]). Waist circumference (cm) was obtained by
measuring the waist in the mean point between the
iliac crests and ribs, with the patient standing after
expiration. The systolic and diastolic blood pressures
(mmHg) were measured with the patient in sitting
position after 5 minutes of rest.Cardiovascular disease
Macrovascular disease was obtained from the medical
clinical history. A history of cardiovascular events was
defined as a history of acute myocardial infarction,
coronary bypass surgery, angioplasty, angina pectoris,
peripheral vascular disease or stroke.
Additionally, the intima-media thickness of the common
carotid, carotid bifurcations and internal carotid arteries
was measured non-invasively by two-dimensional ultra-
sound imaging mode, using a Logiq Book XP ultrasound
(General ElectricW) with a linear transducer of 7.5 MHz in
37 patients (12/21 with depression and 25/40 without
depression). Presence of atherosclerotic plaque was
defined as: (1) abnormal wall thickness (defined as an
intima-media thickness >1.5 mm), (2) abnormal structure
(protrusion into the lumen, loss of alignment with the
adjacent wall) and (3) abnormal echogenicity of the wall
[14]. Increased intima-media thickness was defined as
greater than 0.8 mm. An ankle-brachial index was mea-
sured according to a standard protocol by trained techni-
cians. Briefly, the participant was asked to lie flat on an
examination table, and after 5 minutes of rest, standard
arm blood pressure cuffs were applied to the right arm
and to each ankle (with the lower end of the bladder
within 3 cm of the malleoli). A Doppler vascular probe
(7.5 MHz, General Electric) and a standard mercury
manometer were used to assess systolic blood pressure in
the right brachial artery and in each posterior and anterior
tibial artery in rapid succession. The ankle-brachial index
in the right and left leg was calculated by dividing the
right and the left ankle pressure by the brachial pressure.
Of the ankle-brachial index values obtained in each leg,the lower was used in all analysis. A value between 0.9 and
1.3 was considered normal [15].
Measures
Fasting glucose was measured with the UV-hexokinase
method on a Synchron LX20 (Beckman-Coulter) and
HbA1C by HPLC on a Variant II instrument (Bio-Rad
Laboratories). A fasting lipid profile was also obtained.
Cholesterol in serum was measured by an enzyma-
tic method on a Synchron LX 20 (Beckman Coulter).
Triglycerides were measured by an enzymatic/GPO-
Trinder method on a Synchron LX 20 (Beckman-Coulter).
HDL cholesterol was measured by a homogeneous method
on the same instrument. The LDL cholesterol concentra-
tion was calculated with the Friedewald formula when the
serum triglyceride concentration was <400 mg/dL. Apo B
was measured by nephelometry on an Immage (Beckman-
Coulter). High Sensitivity CRP was measured by a latex
turbidimetric method on a Synchron LX20 (Beckman-
Coulter). The human TNF-α was measured by an immu-
noenzymetric assay (Biosource Europe S.A.). Twenty four
hour urine free cortisol levels and 23.00 pm saliva cortisol
were collected in the outpatient setting and were measured
by radioimmunoassay. All the parameters were measured
in a centralized laboratory.
Statistical analysis
The statistical evaluation of data was performed using
commercially available SPSS Statistics 17.0 software.
Student t tests were applied to compare means for
normally distributed variables and Mann-Whitney test for
variables without normal distribution. Relative frequencies
were calculated and a chi-square analysis was conducted.
Data were expressed as mean ± standard deviation (SD) or
median and interquartile range. Multivariable logistic
regression was used to determine the relative odds of
clinical cardiovascular disease in individuals with depres-
sion compared to those without depression. Because of
the small sample size, only two covariates at a time, deter-
mined to be different by depressive status in univariate
analyses, were adjusted for. Differences were considered
significant using a two-sided p < 0.05.
Results
Participant characteristics
Following psychiatric evaluation, 61 participants (mean
age 62 ± 7 years) were classified into two groups: 21
patients (34%) with MDD and 40 patients (66%) without
depression. The characteristics of individuals with and
without depression are summarized in Table 1. There
was not significant difference in ratio of male/female
patients, age, diabetes duration, insulin therapy, weight,
BMI, waist circumference or systolic or diastolic blood
pressure between the groups. There was also no
Table 1 Participant characteristics by depressive status
Depressive
group (n = 21)
Non-depressive
group (n = 40)
P value
Male/female patients, n (%) 9 (42.9%) / 12
(57.1%)
21 (52.5%) / 19
(47.5%)
ns
Age 63 ± 7.8 62 ± 6.3 ns
Diabetes duration (years) 14 ± 10.2 12 ± 6.8 ns
Insulin treatment, n (%) 12 (57.1%) 19 (47.5%) ns
Weight (Kg) 82.7 ± 22.9 85.9 ± 14.5 ns
BMI (Kg/m2) 31.7 ± 6.1 30.8 ± 5.2 ns
Waist circumference (cm) 106.9 ± 11.9 105.6 ± 11.4 ns
Systolic blood pressure
(mmHg)
141.0 ± 13.7 136.4 ± 14.4 ns
Diastolic blood pressure
(mmHg)
81.4 ± 8.2 80.8 ± 7.1 ns
Data are express as mean ± SD. Student T test or Mann-Whitney test were
applied appropriately. Differences were considered significant when p < 0.05.
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group = 5/21 (24%); non-depressive group = 7/40 (18%).
The prevalence rates of depression in type 2 diabetes
in uncontrolled studies are between 17.8 and 39%, with
higher much lower rates in controlled studies (between
3.2 and 6.5%). [10] Our study reflects similar rates of the
comorbidity than previously published data.Metabolic parameters
Several metabolic parameters were assessed and no
significant differences were found between groups in
glycemic control, lipid profile, ApoB, or TNFα (Table 2).
However, compared to those without depression, indivi-
duals with depression had significantly higher CRP levels
(4.1(1.9-7.6) vs 1.5(0.5-4.4) mg/l; p = 0.02; Mann WhitneyTable 2 Metabolic parameters by depressive status
Depressiv
Glycemia (RV: 70-110 mg/dl) 16
HbA1c (RV: 5-5.8%) 7
Cholesterol (RV: 110-200 mg/dl) 17
LDL (RV: <100 mg/dl) 10
HDL (RV: >40 mg/dl) 46
Triglycerides (RV: 50-150 mg/dl) 13
ApoB (RV: female: 51-171 mg/dl; male: 56-162 mg/dl) 89




Urinary free cortisol (RV: 100.0 ug/24 h) 71
Saliva cortisol (RV: 0.7-5.0 nmol/l) 3
Data are express as mean ± SD. CRP and TNF are express as median and interquarti
Differences were considered significant when p < 0.05.test) and 24-hour urine free cortisol (71.4 ± 21.3 vs 59.8 ±
29.3 ug/24 h; p = 0.03; Mann Whitney test).Cardiovascular disease
There was a significantly higher prevalence of total
cardiovascular events in individuals with depression
compared to those without depression: 38% (n = 8) for
the depressive group vs 15% (n = 6) for non-depressive
group (Chi-square test, p = 0.04) with a stronger asso-
ciation in males compared to females (Chi-square
test, p = 0.01). Compared to the non-depressive group,
those in the depressive group had a 3.5-fold greater odd of
having clinical cardiovascular disease (Table 3). This asso-
ciation persisted following adjustment for UFC and
become stronger following adjustment for CRP.
There was a trend toward a higher prevalence of athero-
sclerotic plaque among depressed compared to non-
depressed individuals (75% for the depressive group vs 44%
for non-depressive group; p = 0.07); however, the difference
was not statistically significant, likely due to the smaller
number of patients (n = 37) who underwent carotid ultra-
sound measurements. There was no significant difference
in carotid intimal-medial thickness or ankle-brachial indices
between the two groups (data not shown).Discussion
Multiple biological links that potentially mediate the
adverse effect of comorbid depression on diabetes-related
and cardiovascular mortality have been described.
These include increased pro-inflammatory cytokines,
abnormalities of the hypothalamic pituitary axis (HPA),
changes in homeostasis between the sympathetic and
parasympathetic nervous systems and changes in
metabolism [16-19].e group (n = 21) Non-depressive group (n = 40) P value
1.9 ± 54.9 143.7 ± 38.2 ns
.4 ± 1.1 7.5 ± 1.1 ns
5.9 ± 34.6 170.0 ± 29.83 ns
2.6 ± 29.8 102.1 ± 28.6 ns
.3 ± 11.0 41.8 ± 9.9 ns
3.0 ± 70.3 130.8 ± 65.6 ns
.3 ± 19.6 87.8 ± 18.0 ns
(1.9-7.6) 1.5(0.5-4.4) 0.02
(8.4-27.4) 11.9(9.1-20.5) ns
.4 ± 21.3 59.8 ± 29.3 0.03
.1 ± 1.9 2.2 ± 1.4 ns
le range. Student T test or Mann-Whitney test were applied appropriately.
Table 3 Relative odds (95% confidence intervals) of
clinical cardiovascular disease by depressive status
Model OR 95% CI p-value
Unadjusted 3.49 (1.01, 12.0) 0.048
UFC-adjusted 3.88 (1.00, 15.0) 0.05
CRP-adjusted 7.44 (1.65, 33.5) 0.009
UFC and CRP adjusted 9.51 (1.75, 51.7) 0.009
Reference group: Non-depressive; UFC = urine free cortisol;
CRP = C-reactive protein.
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depression had significantly higher 24-h urine free cortisol
levels and CRP than individuals without depression. While
there was a trend toward higher late-evening salivary
cortisol in individuals with depression compared to
those without depression, this difference was not
statistically significant.
There were no differences in glycemic and metabolic
control or subclinical atheroscleorsis between the two
groups. This association persisted following adjustment
for UFC and became stronger after adjusting for CRP.
Our depressed patients tended to be older in age,
to have a longer duration of diabetes and a higher
percentage were receiving insulin treatment. However,
none of these trends were statistically significant.
Our study confirms prior findings that MDD is asso-
ciated with subclinical hypercortisolism and HPA axis
activation and increased levels of some inflammatory
markers [20-23] and that these associations are present
among depressed individuals with type 2 diabetes.
We hypothesized that these physiological abnormalities
associated with MDD might explain the higher prevalence
of clinical cardiovascular events that we found in the
depressed individuals. Hypercortisolism produces increased
visceral adiposity by stimulating increased adipocyte size
and number [24] and visceral adiposity is a risk factor for
cardiovascular disease [25]. Activation of the HPA axis
results in simultaneous activation of the sympathetic
nervous system, which in turn stimulates release of IL-6,
inducing an inflammatory cascade [16]. Elevated CRP and
IL-6 has been shown to predict development of cardiovas-
cular disease [26]. UFC and inflammatory markers could
explain in part our observed association; however, our
results should be interpreted with caution given the small
sample size.
Our study has several strengths. First, our partici-
pants had physician-confirmed diagnosis for both
depression and diabetes status using standardized
assessment methods as opposed to questionnaires or
self-report. We were also able to characterize several
biological determinants in the association between
depression and cardiovascular disease in individuals
with diabetes, including measures of HPA axisactivity (i.e. 24-hour urine free cortisol and salivary
cortisol) and inflammatory markers.
However, our study has some weaknesses that should
be kept in mind when interpreting our data. First, our
sample size was small, which may have limited our
power to examine other associations. Second, our study
was cross-sectional, which does not allow us to deter-
mine the temporality of association between depression,
biological factors, and clinical cardiovascular events
among those with diabetes. Finally, our participants were
recruited from one race/ethnicity, which may limit the
generalizability of findings to other populations.
Conclusions
Our study showed that people with diabetes and depression
are more likely to have cardiovascular events than non-
depressed patients. The higher levels of CRP and urinary
cortisol did not appear to explain the higher number
of cardiovascular events, suggesting that other biological
factors, such as alterations in the serotonin system, may
also be implicated. Larger studies are needed to elucidate
the biological mechanisms linking depression to cardio-
vascular disease in diabetes to identify targets for future
preventive interventions.
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